Renovaro raises $2M in private placement; converts $2M debt into equity

Lunai Bioworks Inc.

Issued 280,005 units at $7.13/unit for $2M cash; each unit = 1 Series A Convertible Preferred share + warrant for 5 common shares.
Converted $2M of promissory note into 280,505 units on same terms, leaving $3M note outstanding.
Preferred stock convertible into common at 10:1; warrants exercisable at $0.65/share for 5 years.
Offering under Regulation S, no underwriter; proceeds for general corporate purposes.

item 1.01 item 3.02 item 3.03 item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Lunai Bioworks Inc.: Filed Certificate of Designation for Series A Convertible Preferred Stock establishing rights and preferences (effective 2023-08-01).

Change: charter amendment
Effective: 2023-08-01

Exact text from the filing

On August 1, 2023, the Company filed with the Secretary of State of the State of Delaware the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the “ Certificate of Designation ”) establishing the series of Preferred Stock designated as the Series A Convertible Preferred Stock with the rights and preferences discussed below.

View on SEC.gov

86 governance changes filed in the last 30 days. Browse all governance changes →

Lunai Bioworks Inc. filing history →

Source: SEC EDGAR

accession 0001731122-23-001396

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.